--- title: "U.S. Stock Market Midday Update: 10X Genomics up 11.14%: Executive sell-off fails to dampen optimism, earnings forecast upgrade boosts confidence" type: "News" locale: "en" url: "https://longbridge.com/en/news/296391273.md" description: "10X Genomics rose 11.14%; Tempus AI rose 23.95%, with a transaction volume of USD 990 million; Thermo Fisher Scientific rose 4.45%, with a transaction volume of USD 829 million; Danaher rose 6.07%, with a transaction volume of USD 772 million; Agilent Technologies rose 4.64%, with a market value of USD 43.9 billion" datetime: "2026-08-19T19:13:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296391273.md) - [en](https://longbridge.com/en/news/296391273.md) - [zh-HK](https://longbridge.com/zh-HK/news/296391273.md) generator: "portal-rs" --- # U.S. Stock Market Midday Update: 10X Genomics up 11.14%: Executive sell-off fails to dampen optimism, earnings forecast upgrade boosts confidence **U.S. Stock Market Midday Update** 10X Genomics rose by 11.14%. Based on recent key news: 1. On August 17, 10X Genomics director Sarah A. Teichmann sold 7,551 shares of Class A common stock at prices of $57.29 and $57.15. This action reduced her direct holdings to 28,058 shares. Nevertheless, market confidence in the company's future appears unaffected, with the stock price rising by 11.14%. Source: EDGAR system disclosure 2. On August 16, the market expressed optimism about 10X Genomics' technological innovations and product line expansion, driving the stock price up. The company's ongoing R&D investment in genomics is considered a key driver of its growth. Source: Zhitong Finance 3. On August 15, analysts raised their earnings expectations for 10X Genomics, anticipating significant revenue growth from its expansion into emerging markets. This positive analyst rating further boosted investor confidence. Source: Morgan Stanley The genomics industry is growing rapidly, with significant capital inflows. **Stocks with High Trading Volume in the Industry** Tempus AI rose by 23.95%. Based on recent key news: 1. On August 20, the personalized mRNA melanoma vaccine jointly developed by Merck and Moderna achieved positive results in Phase III clinical trials, driving up Tempus AI's stock price. The safety and efficacy of this therapy have significantly improved, and Tempus recently announced the acquisition of Personalis for $1.5 billion, validating the value of its acquisition strategy. Source: Zhitong Finance 2. On August 19, Tempus AI director Nadja West sold 3,000 shares of Class A common stock, retaining 34,981 shares afterward. Nevertheless, the stock price still rose due to the vaccine trial results. Source: Public Technologies 3. On August 17, financial reports disclosed a complex transaction between Tempus AI and Pathos, involving a $35 million reverse payment, partially settled with unlisted Series D preferred stock, reflecting certain commonalities in the AI healthcare industry. Source: Wall Street Insight The biotechnology sector rose on favorable vaccine news. Thermo Fisher Scientific rose by 4.45%. Based on recent key news: 1. On August 17, the global president of Thermo Fisher met with officials from the Chinese Ministry of Commerce to discuss U.S.-China trade relations and the company's development in China, boosting market confidence in its business expansion in China and driving up the stock price. 2. On August 18, Thermo Fisher announced that Dan Rosen, Vice President for Southeast Asia, was appointed as President for the China region, which is expected to strengthen the company's leadership and business development in the Chinese market, further boosting the stock price On August 19, the Mayor of Shanghai met with Thermo Fisher Scientific's CEO to discuss cooperation in the biopharmaceutical industry. The Shanghai municipal government supports Thermo Fisher's investment in Shanghai, enhancing market expectations for the company's future development. The biopharmaceutical industry has recently shown strong performance, with significant capital inflows. Danaher rose 6.07%. Based on recent key news: 1. On August 19, MarketBeat reported that although Danaher was rated "Moderate Buy" by analysts, it was not included in the list of the top five stocks recommended by leading analysts. This indicates a lack of confidence in Danaher from the market, which may affect investor sentiment. 2. On August 17, MarketBeat's analysis showed that despite Danaher receiving a "Moderate Buy" rating, analysts are more optimistic about five other stocks. This may lead some investors to reassess their portfolios, impacting stock price fluctuations. Market capital inflows have increased, and industry trends are positive. **Stocks ranked among the top in industry market capitalization** Agilent Technologies rose 4.64%. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. no\_news ### Related Stocks - [TXG.US](https://longbridge.com/en/quote/TXG.US.md) - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [TMO.US](https://longbridge.com/en/quote/TMO.US.md) - [DHR.US](https://longbridge.com/en/quote/DHR.US.md) - [A.US](https://longbridge.com/en/quote/A.US.md) ## Related News & Research - [10x Genomics director Sarah A. Teichmann disposes of USD 433,106 in common shares](https://longbridge.com/en/news/296141275.md) - [10x Genomics director John R. Stuelpnagel sells 20,000 shares worth $1.15 million](https://longbridge.com/en/news/295839755.md) - [10x Genomics $TXG Shares Acquired by Sei Investments Co.](https://longbridge.com/en/news/295765945.md) - [10x Genomics Q2 revenue rises on Atera demand](https://longbridge.com/en/news/295139323.md) - [TXG: Los Reyes targets 37% IRR, $1.5B NPV, and first production in 2031 with strong margins](https://longbridge.com/en/news/291983354.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**